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Simple Summary: Multiple myeloma (MM) is a still uncurable tumor of mainly elderly patients
originating from the terminally differentiated B cells. Introduction to the treatment of MM patients
of a new class of drugs called proteasome inhibitors (bortezomib followed by carfilzomib and
ixazomib) significantly improved disease control. Proteasome inhibitors interfere with the major
mechanism of protein degradation in a cell leading to the severe imbalance in the protein turnover
that is deadly to MM cells. Currently, these drugs are the mainstream of MM therapy but are also
associated with an increased rate of the injuries to multiple organs and tissues. In this review,
we summarize the current knowledge on the molecular mechanisms of the first-in-class proteasome
inhibitor bortezomib-induced disturbances in the function of peripheral nerves and cardiac and
skeletal muscle.
Abstract: The overall approach to the treatment of multiple myeloma (MM) has undergone several
changes during the past decade. and proteasome inhibitors (PIs) including bortezomib, carfilzomib,
and ixazomib have considerably improved the outcomes in affected patients. The first-in-class
selective PI bortezomib has been initially approved for the refractory forms of the disease but has now
become, in combination with other drugs, the backbone of the frontline therapy for newly diagnosed
MM patients, as well as in the maintenance therapy and relapsed/refractory setting. Despite being
among the most widely used and highly effective agents for MM, bortezomib can induce adverse
events that potentially lead to early discontinuation of the therapy with negative effects on the quality
of life and outcome of the patients. Although peripheral neuropathy and myelosuppression have
been recognized as the most relevant bortezomib-related adverse effects, cardiac and skeletal muscle
toxicities are relatively common in MM treated patients, but they have received much less attention.
Here we review the neuromuscular and cardiovascular side effects of bortezomib. focusing on the
molecular mechanisms underlying its toxicity. We also discuss our preliminary data on the effects of
bortezomib on skeletal muscle tissue in mice receiving the drug.
Keywords: multiple myeloma; proteasome inhibitors; bortezomib; peripheral neuropathy;
cardiotoxicity; muscle toxicity
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1. Introduction
Multiple myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of malignant
plasma cells in the bone marrow, monoclonal protein in the blood and/or urine, and evidence of specific
end-organ damage including hypercalcemia, renal failure, anemia, and osteolytic bone lesions [1,2].
The disease is almost always preceded by an asymptomatic premalignant stage termed monoclonal
gammopathy of undetermined significance (MGUS), with or without an identified intervening stage of
smoldering multiple myeloma (SMM) [3,4].
MM is the second most common hematological malignancy in adults and accounts for about
1.8% of all cancers and 10% of all blood ones in the United States with an annual incidence of 7.0 per
100,000 [4]. It affects mainly the older population with a median age of patients at diagnosis of 69 years,
is more common in men and among people of African American descent [5]. Despite the significant
progress in available therapies and the improvement in the outcome of patients, MM remains an
incurable disease with a 5-year relative survival rate of 53.9% [5–7].
The overall approach to MM treatment has dramatically changed over the last two decades.
New classes of drugs have been added to the traditional armamentarium (corticosteroids, alkylating
agents, and anthracyclines), and, along with high-dose chemotherapy followed by autologous
hemopoietic stem cell transplantation, have led to a longer-lasting clinical response in these patients.
Novel agents include proteasome inhibitors, immunomodulatory drugs (thalidomide, lenalidomide,
pomalidomide), histone deacetylase inhibitors (panobinostat), monoclonal antibodies directed against
CD38 (daratumumab and isatuximab) or signaling lymphocytic activation molecule F7 (SLAMF7,
elotuzumab), and nuclear export inhibitors (selinexor) [8,9]. Currently, MM therapy is based on
regimens that combine agents having different mechanisms of action.
Proteasome inhibitors (PIs) have been proved to be effective in MM patients and include the
first-in-class PI bortezomib, the second-generation inhibitor carfilzomib, and ixazomib, the first oral
PI [10]. These drugs target the 26S proteasome, a multi-subunit ATP-dependent enzymatic complex of
the ubiquitin-proteasome system (UPS), the major protein degradation pathway in eukaryotic cells [10].
The proteasome is made up of a barrel-shaped core particle consisting of four stacked heptameric
rings, referred to as the 20S proteasome, and two 19S regulatory particles at the extremities [10].
Proteasome substrates include misfolded, damaged, or mutant proteins and short-lived regulatory
proteins that need to be removed for proper cellular function [10]. The accumulation of aberrantly
folded proteins in the endoplasmic reticulum (ER) lumen can affect ER homeostasis and lead to
a condition referred to as ER stress [10]. One pathway of relieving ER stress is the ER-associated
degradation (ERAD) by which unfolded/misfolded proteins undergo retrotranslocation to the cytosol
and are degraded by UPS [11,12]. By inhibiting the 26S proteasome, PIs halt ERAD and cause protein
overload within the ER [11,12]. MM cells, because of their high protein turnover due to immunoglobulin
overproduction, are particularly susceptible to proteasome inhibition [13]. Other proven mechanisms
of anti-myeloma activity of PIs include the induction of oxidative stress due to excessive production
of reactive oxygen species, which further exacerbates protein misfolding but also damages DNA,
inevitably leading to cell death [14].
2. Bortezomib: The First-in-Class Proteasome Inhibitor
The introduction of bortezomib (also known as PS 341 and Velcade™), approved by the US
Food and Drug Administration (FDA) in 2003, represented a breakthrough in the treatment of MM.
The drug is currently indicated for both newly diagnosed and relapsed and/or refractory forms of
MM [15,16] and can be used in combination with other agents in stem cell-eligible patients, both in
induction and in consolidation or maintenance therapy, as well as in patients not eligible for stem cell
transplantation [8,17]. Bortezomib is a reversible boronic acid dipeptide which binds primarily the β5
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subunit and, to a lesser extent, the β2 and β1 subunits of the catalytic 20S proteasome, blocking its
chymotrypsin-like, trypsin-like and caspase-like activities, respectively [18,19]. Evidence that point
mutations in the gene encoding the proteasome β5 subunit (PSMB5) result in bortezomib resistance
suggests that this subunit is the clinically relevant target of the drug [20–22].
Besides inducing ER stress in MM cells [23,24], bortezomib prevents the degradation of an
inhibitory molecule IκB with the consequent suppression of transcription factor nuclear factor-κB
(NF-κB) pathway, which regulates the expression of genes involved in cell growth and survival,
cell cycle regulation, angiogenesis, inflammation, interactions between tumor cells and bone marrow
stromal cells, and anti-apoptotic mechanisms [25]. Other proposed mechanisms of cellular toxicity
induced by bortezomib are the direct induction of caspase-mediated apoptosis via the activation of the
c-Jun NH2-terminal kinase (JNK) pathway and the phosphorylation of p53, and the cell-cycle G1 arrest
via increased levels of cyclin-dependent kinase inhibitors p27 and p21 [26,27] (Figure 1).
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(52%), nausea (55%), diarrhea (44%), thrombocytopenia (40%), peripheral neuropathy (31%), 
vomiting (27%), anorexia (25%), pyrexia (22%) and anemia (21%) [29]. The major grade 3 adverse 
reactions included thrombocytopenia (28%), fatigue (12%), neuropathy (12%), and neutropenia 
(11%), and fourteen percent of the patients experienced at least one episode of severe toxicity (grade 
4), most commonly hematologic including thrombocytopenia (3%) and neutropenia (3%) [29]. The 
major adverse effects reported in the following APEX phase III trial were consistent in type and 
frequency with those previously described [30]. 
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Despite being a ong the ost idely used and highly effective treat ent options for ,
bortezo ib can induce adverse events that potentially lead to early discontinuation of the therapy with
a negative impact on the quality of life and outcome of the patients (Figure 2). The drug is available for
intravenous injection or subcutaneous use [28]. Based on data from the multicenter phase II open-label,
single-arm (SUMMIT) trial, which led to the FDA approval of the drug, the most frequently reported
all-grade side effects were asthenic conditions including fatigue and weakness (52%), nausea (55%),
diarrhea (44%), thrombocytopenia (40 ), peripheral neuropathy (31%), vomiting (27%), anorexia (25 ),
pyrexia (22%) and anemia (21%) [29]. The major grade 3 adverse reactions included thrombocytopenia
(28%), fatigue (12%), neuropathy (12%), and neutropenia (11%), and fourteen percent of the patients
experienced at least one episode of severe toxicity (grade 4), most commonly hematologic including
thro bocytopenia (3%) and neutropenia (3%) [29]. The major adverse effects reported in the following
APEX phase III trial were consistent in type and frequency with those previously described [30].
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case reports, bortezomib was associated with prominent and progressive motor neuropathy 
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3. Peripheral Neuropathy: The Key Dose-Limiting Toxicity
Peripheral neuropathy represents one of the most common, unpredictable, and dose-limiting
non-hematologic adverse events of MM treatment with bortezomib, which often requires dose
modification, delay, or discontinuation of the drug. Bortezomib-induced peripheral neuropathy (BIPN)
negatively affects clinical endpoints with a detrimental effect on the quality of life of patients and is
associated with a significant economic impact, which adds up to the costs directly related to disease
therapy [31,32].
BIPN is a length-dependent predominant sensory painful neuropathy with the potential
involvement of both large and small nerve fibers. It is clinically characterized by paraesthesia and
numbness with symmetric “glove and stocking” distribution, and by neuropathic pain, mostly affecting
fingertips and toes [31]. Neurological examination reveals distal multimodal sensory loss and reduced
or absent deep tendon reflexes while peripheral nerve motor impairment is usually subclinical [33].
Symptoms of autonomic dysfunction, including orthostatic hypotension, postural dizziness, syncope,
diarrhea, paralytic ileus, and urinary disturbances have been reported [34–36] and are likely due
to bortezomib toxicity of the pre- and post-ganglionic autonomic nerve fibers of the sympathetic
and parasympathetic nervous system [34,37,38]. Nerve conduction studies reveal a predominantly
axonal or mixed polyneuropathy, although primarily demyelinating features have been occasionally
reported [39–43]. Needle electromyography may record neurogenic motor unit potentials with active
denervation in the distal muscles of the lower extremities [31]. Usually, cerebrospinal fluid analysis is not
informative [31]. In a handful of individual case series or single case reports, bortezomib was associated
with prominent and progressive motor neuropathy [38,40,41,43–47]. This condition has been ascribed
to an immune-mediated mechanism for the frequent finding of albumin-cytological dissociation in the
cerebrospinal fluid and for the favorable response to corticosteroids, intravenous immunoglobulin,
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or plasma exchange [38,40,41,43,45–47]. Moreover, in a few patients, a vasculitis process has been
observed on nerve pathological examination [38,47].
A retrospective analysis of 8218 MM patients included in phase 3 randomized control trials with
bortezomib reported an overall incidence of peripheral neuropathy (all grades) ranging from 8.4% to
80.5% (median 37.8%) and of severe neuropathy (grades 3 and 4) ranging from 1% to 33.2% (median
8%) [48]. The incidence and the severity of the neuropathy were similar for both newly diagnosed and
relapsed MM patients [48,49]. Due to neurotoxicity, the drug was reduced in 12% and discontinued in
5% of the patients [50].
The incidence and severity of peripheral neuropathy depend on the cumulative drug dose,
the dosing schedule, and the route of administration. Neurotoxicity generally develops within the first
cycles of treatment using the standard dose and schedule, and reaches a plateau after five 3-week cycles
at a cumulative dose of 42 mg/m2 in relapsed MM or after three 6-week cycles at a cumulative dose
of 45 mg/m2 in newly diagnosed MM [33,50]. There is no evidence of new cumulative neurotoxicity
upon retreatment with bortezomib [51,52]. The once per week and the subcutaneous bortezomib
administration are associated with a significantly lower rate of neuropathy compared to the twice
per week regimen and the intravenous route, without efficacy reduction [49,53–55]. Despite its
frequency and severity, BIPN presents a potentially favorable outcome. Dose reduction, modification in
the route or schedule of administration, and ultimately withdrawal of therapy can improve and
sometimes resolve the neuropathy [56,57]. The median time to recovery is approximately three
months [49,58,59]. However, neurotoxicity can be an adverse event that continues to affect patients
after treatment has ceased, and up to 30% of patients may be left with persistent neuropathy [33,60].
BIPN is not preventable, and the treatment approach is limited to symptomatic therapies aiming at
reducing neuropathic pain [61]. Immune therapy should be considered if there is any evidence of
immune-mediated neuropathy.
Possible predisposing factors for the development of the treatment-emergent neuropathy have been
identified. A pre-existing neuropathy significantly increases the risk of developing BIPN [31,58,62,63].
The peripheral nerve involvement may depend on previous chemotherapy or can be related to the
hematologic disease itself [49]. Clinical signs of peripheral neuropathy or subclinical neurophysiological
abnormalities have been observed in up to 54% of patients with previously untreated symptomatic
MM [64]. It is not clear if the combination of thalidomide, a neurotoxic agent, and bortezomib results
in a higher susceptibility to peripheral nerve toxicity [48]. Advanced age has been proposed as a risk
factor for drug-induced peripheral neuropathy [65,66]; however, this relationship was not confirmed
in larger trials [50,58] suggesting that elderly patients without any significant comorbidities should be
treated with the optimal bortezomib dose [33]. Diabetes and impairment of renal function have been
ruled out as predisposing factors for neuropathy [49]. Intriguingly, neurotoxicity is more frequent in
patients with MM than in those with other malignancies, suggesting that the disease itself may have a
role in the development of neuropathy in bortezomib-treated patients [49].
The pathogenesis of BIPN is not yet fully elucidated. In vivo and in vitro experimental studies
have been designed to characterize the pathological features of the neuropathy and to understand the
mechanisms through which bortezomib exerts its toxicity on the peripheral nervous system.
Due to the absence of the blood-brain barrier that bortezomib cannot cross, peripheral axons
and dorsal root ganglia (DRG) of primary sensory neurons are selectively vulnerable, whereas the
motoneurons in the anterior horn of the spinal cord are usually spared [67,68]. As mentioned above,
bortezomib-treated patients, in most cases, present a sensory neuropathy and neuropathic pain with
impairment of afferent large myelinated Aβ fibers as well as of small, thinly myelinated Aδ and
unmyelinated C fibers [69,70]. Severely reduced autonomic nerve fiber densities were also observed in
skin biopsies of treated patients suggesting that bortezomib can cause neuropathy involving somatic
as well as autonomic small fibers with a length-dependent pattern [34].
Animal models for BIPN reproduce the findings observed in the clinical setting.
Neuropathological examination of peripheral nerves from adult rats exposed to bortezomib three
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times per week for 8 weeks or twice per week for 4 weeks and from mice receiving bortezomib twice
per week for 6 weeks documented morphological abnormalities and/or reduction of myelinated and
unmyelinated fibers with possible concurrent impairment of DRG of sensory neurons and satellite
cells [68,71–74]. Pathological changes in sensory nerves consisted of vacuolization and disorganization
of fiber axoplasm [71]. Alterations of Schwann cells and myelin sheaths have also been described in
both rat and mice models, although bortezomib mainly induces an axonopathy without significant
impairment of internodal myelin structure [75–77]. As already mentioned, in rare cases, bortezomib can
also induce neuropathy with predominant demyelinating features based on electrodiagnostic and
histopathological findings [39–41,47].
Different hypotheses have been raised on the molecular mechanisms underlying these alterations.
It has been suggested that mitochondria are one of the main targets of bortezomib in the peripheral
nervous system. In the rat model of BIPN, swollen and enlarged mitochondria were observed
in axons, Schwann cells, DRG satellite cells, and occasionally in DRG neurons, associated with a
dysfunction in mitochondrial respiration with reduced complex I and II enzyme activities and ATP
production [76,78,79]. Impaired mitochondrial function can induce the formation of reactive oxygen
species and, as in MM cells [80], a dysregulation of intracellular Ca2+ homeostasis, both mechanisms
being potentially neurotoxic [81]. Moreover, reduced ATP production could impair the function of
the Na+-K+-ATPase-dependent pump with early negative effects on axonal membrane excitability,
thus contributing to the neuropathic pain [82]. Despite the mechanisms leading to mitochondrial
defects remain unknown, their dysfunction is considered an indirect effect of cytosolic proteasome
inhibition rather than an off-target effect of bortezomib [78,79]. The “mitotoxicity hypothesis” has been
proposed also for other chemotherapeutic agents, such as taxanes and platinum agents [83,84].
It has been shown that some drugs act on microtubule depolymerization and polymerization with
the consequent disruption of processes necessary for cell survival, including intracellular transport,
cell motility, maintenance of cell structure, and mitosis [85]. In vitro studies showed impaired axonal
growth and axonal degeneration in neonatal and adult primary neuron cultures treated with MG132
and lactacystin, two other 26S proteasome inhibitors [86,87]. Bortezomib has been demonstrated to
induce increased tubulin polymerization and stabilization of microtubules in neuronal cell lines as well
as in rat embryonic and adult DRG neurons [88,89]. The mechanism promoting tubulin polymerization
does not derive from a direct microtubule-binding as occurs for paclitaxel [85], but it is probably
due to a selectively increased level of MAP2, a microtubule-associated protein [88] as a result of
proteasome inhibition. The altered microtubule dynamics result in decreased neurite elongation and
impaired axonal transport of mitochondria in mice and rat DRG neuronal cultures, respectively [90,91].
In addition, bortezomib can affect another major component of the cytoskeleton, the actin filaments,
as observed in mouse neural stem cells [92].
Besides the effects on mitochondria and cytoskeleton, bortezomib acts at the nuclear level in primary
sensory neurons, without affecting their survival [67,93]. In DRG neurons of adult Sprague-Dawley
rats treated with low doses of bortezomib, nuclei were displaced in an eccentric position and resulted
in irregular shape and altered polarity [93]. Ultrastructural analysis of DRG neurons documented a
partial chromatolysis with dissolution of Nissl Bodies and retention of polyadenylated RNAs in nuclear
granules, suggesting that bortezomib could interfere with mRNA processing, thus causing impairment
of protein synthesis [67]. In support of this, reduced expression of the brain-derived neurotrophic
factor (BDNF), a neuronal growth factor that is crucial for neuronal survival and repair, was observed
in dysfunctional neurons [93].
Recently, a dysregulation of the sphingolipid metabolism, which may contribute to the
development of neuropathic pain was demonstrated in the dorsal horn of the spinal cord from
rats exposed to bortezomib [94]. These findings highlight that bortezomib affects different
intracellular processes.
Several clinical and histopathological data suggest that also inflammation might be a relevant
factor in the onset and course of BIPN [38,40,47]. A small-sized multicentre phase II trial reported a
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shift in the T helper type 1 (Th1)/ T helper type 2 (Th2) cytokine balance towards Th2 dominance with
elevated levels of interleukin-6 (IL-6) in the peripheral blood of patients who developed a painful
neuropathy during treatment with bortezomib [95]. The role of immunity in bortezomib-induced
neurotoxicity, however, remains controversial since mice immunocompromised by X-ray irradiation
before bortezomib treatment displayed the same peripheral neuropathy of immunocompetent mice [72].
Conversely, in animal models of bortezomib-induced neuropathy, the increased expression of TNF-α,
a proinflammatory cytokine associated with the development of neuropathic pain [96–99], has been
observed in the neurons of DRG and spinal dorsal horn [100–102]. Blockade of TNF-α signaling
prevents the loss of myelinated and unmyelinated peripheral nerve fibers [100] and can hamper the
onset of neuropathic pain in animal models for this condition [101–104]. One of the main mechanisms of
action of bortezomib in cancer cells is the inhibition of the NF-κB pathway by blocking the proteasome
degradation of its negative regulator IkB with consequently reduced production of proinflammatory
cytokines including TNF-α [105,106]. In contrast to cancer cells, bortezomib seems to activate NF-κB
in DRG neurons of treated mice independently of the presence of its natural inhibitor, thus leading to
an upregulation of proinflammatory cytokines [100]. Indeed, neuropathy is significantly less severe in
mice with impaired NF-κB activation than in wild-type animals [107].
4. Cardiovascular Toxicity: The Low Rate and Reversible Side Effect
There are ambiguous and conflicting data on the influence of bortezomib on cardiac function
and its potential cardiotoxicity is still a matter of debate. This partly depends on whether the drug
is used in patients with significant cardiovascular disease risk factors and on previous exposure to
known cardiotoxic chemotherapeutic agents such as anthracyclines, making it difficult to determine if
a single or a combination of factors cause the cardiac events [108,109]. However, since bortezomib
has been approved to be used in the clinical setting, many reports have been published addressing its
cardiovascular toxicity [110–126]. The cardiovascular adverse events so far associated with bortezomib
treatment include heart failure, that is the most frequently reported cardiac side effect [110–120],
conduction disorders such as complete atrioventricular block [110,121–123], arrhythmias including
atrial fibrillation [110,124], ischemic heart disease [125], pericardial effusion [112,126] and orthostatic
hypotension [27,115].
A systematic review and meta-analysis of 25 prospective phase II and phase III trials
evaluating bortezomib in the treatment of different malignancies including MM, lymphoma,
Waldenström macroglobulinemia, non-small cell lung cancer, and ovarian cancer concluded that it does
not significantly increase the risk of cardiac adverse events as compared to control medications, with an
incidence of all grade and high-grade cardiotoxicity in all patients of 3.8% and 2.3% respectively [127].
The overall cardiac safety profile of bortezomib was confirmed in a later retrospective analysis of
patients included in the phase 2 registration study for the US and EU regulatory approval and in all
phase 3 studies that led to the US and EU regulatory approval [128]. The study showed no significant
differences in the incidence of cardiovascular toxicities between bortezomib- and non-bortezomib
based arms. The incidence of grade ≥3 heart failure was 1.2–4.7%, with a low incidence of grade
≥3 ischemic heart disease (0.4–2.7%), arrhythmias (0.6–4.1%), and cardiac death (0–1.4%) [128]. In a
recent prospective observational study, 17% of 30 patients with relapsed MM receiving bortezomib
manifested cardiovascular adverse events confirming a low rate of cardiac toxicity of this drug
compared to carfilzomib [129]. Cardiac complications usually occur within the first three months of
treatment and mostly in patients with multiple cardiovascular risk factors, raising the possibility of
a synergistic effect [129,130]. Cardiovascular side effects often improve with the withdrawal of the
therapy, but medication, hospitalization, and pacemaker implantation may be required [110,112,115].
In the heart, the ubiquitin-proteasome system (UPS) is important in different intracellular
pathways and its dysfunction has been suggested to play a pathogenetic role in cardiac diseases
including cardiomyopathies, heart failure, ischemia-reperfusion injury, and atherosclerosis [131–134].
In vitro studies demonstrated that bortezomib at submicromolar concentrations inhibits reversibly the
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chymotrypsin-like proteasomal activity also in primary neonatal rat cardiomyocytes besides cancer
cells [135,136]. Hence, it is reasonable to suppose that the drug could induce cardiac damage.
Cardiovascular effects of bortezomib have been addressed in several in vivo studies that led to
contradictory results. Left ventricular systolic and diastolic function was preserved and no distinct
morphological myocardial abnormalities were detected in adult male rabbits exposed to bortezomib
alone for 10 weeks [136]. Conversely, male Wistar rats treated thrice weekly with bortezomib for
3 weeks developed a reversible cardiac dysfunction with a significant decrease in left ventricular ejection
fraction and showed myocardial changes with scattered enlarged and vacuolated cardiomyocytes [137].
Bortezomib treatment induced left ventricular hypertrophy in 10-week-old mice subjected to sham
surgery and resulted in heart failure and premature death in animals with aortic constriction [138,139].
Interestingly, three-month-old female pigs exposed for 12 weeks to MLN273, a proteasome inhibitor
structurally and functionally related to bortezomib [140–142], developed hypertrophic-restrictive
cardiomyopathy with a significant increase of myocardial perivascular and interstitial fibrosis [143].
The pathogenic mechanisms potentially involved in bortezomib-induced cardiovascular toxicity
remain largely to be elucidated. Myocardial cells are post-mitotic terminally differentiated cells
with finely tuned metabolism and function, and limited capacity for division and proliferation.
Quality control of structural and functional proteins and efficient removal of damaged cellular
components play a key role in maintaining myocardial viability and regulating its functions [144]. In rat
cardiomyoblast H9c2 cells, bortezomib, by inhibiting proteasomal activity, causes the accumulation
of polyubiquitinated proteins which, in turn, leads to ER stress and compensatory autophagy [137].
MG262, a boronic acid-based proteasome inhibitor [142], through the activation of the calcineurin-NFAT
pathway, promotes the translocation of the nuclear factor of activated T-cells (NFAT) into the nucleus
in neonatal rat ventricular myocytes with significant changes in the cell morphology [138]. It has
also been suggested that the inhibition of the proteasome by bortezomib in primary neonatal rat
ventricular myocytes can lead to the activation of caspase-3 and caspase-7 and, consequently, to cellular
apoptosis [135]. Mitochondria have been identified as another possible intracellular, and probably
indirect target of cardiotoxicity because bortezomib inhibits complex V of the mitochondrial respiratory
chain that results in a marked drop in ATP synthesis in the heart of treated rats and a decreased cell
shortening of primary rat left ventricular myocytes [137]. Functional changes paralleled the structural
alterations of the mitochondria, which became pleomorphic and enlarged containing concentric cristae
and electron-dense inclusions and with a tendency to form large intermyofibrillar clusters leading to
misalignment of the myofibrillar network [137]. Both the functional and morphological changes in
this rat model of cardiotoxicity were reversible with full recovery after bortezomib discontinuation,
suggesting that it does not induce irreversible damage of cardiomyocytes, in agreement with the
improvement of heart function observed in MM patients after drug withdrawal [137]. Moreover,
bortezomib-mediated mitochondrial dysfunction might be further explained by a recently described
process of extraction of misfolded proteins from mitochondria, and their subsequent degradation in
proteasomes altogether called mitochondria-associated degradation (MAD) [145]. Similarly to ERAD,
inhibition of proteasome leads to accumulation of misfolded and damaged proteins in mitochondria
resulting in their dysfunction.
It has been proposed that bortezomib-induced vascular effects could be partly responsible for its
potential cardiotoxicity. Thrombotic microangiopathy has been recently described in patients treated
with bortezomib, suggesting its possible direct microvascular toxicity to the endothelium [146]. In vitro
studies demonstrated that bortezomib at clinically achievable concentrations exerts anti-angiogenic
effects on endothelial cells derived from the bone marrow of MM patients and human umbilical vascular
endothelial cells (HUVEC) [147]. Bortezomib mediates anti-angiogenesis both directly by inducing cell
cycle arrest at G2 to M transition and indirectly through the down-regulation of the expression of genes
involved in the angiogenic cascade, including VEGF and IL-6, with consequent growth inhibition
and increased permeability of vascular endothelial cells [147,148]. The reversible peptide aldehyde
MG132 [142] reduces in vitro the number of endothelial progenitor cells and negatively affects their
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function by inducing their apoptosis and impairing the endothelial nitric oxide synthase/nitric oxide
(eNOS/NO) pathway [149,150]. Moreover, in female pigs, the chronic inhibition of proteasome by
MLN273 can lead to endothelial dysfunction and coronary atherosclerosis with reduced myocardial
perfusion response and increased microvascular permeability [141,143]. These data are supported
by human studies that showed decreased proteasomal activity and accumulation of ubiquitinated
substrates in carotid and coronary symptomatic unstable atherosclerotic plaques [151,152]. Therefore,
bortezomib could affect the physiological properties of blood vessels and hasten or aggravate an
already present vascular damage, as it happens in coronary heart disease.
Finally, the impairment of both the sympathetic and parasympathetic nerve fibers [34,37] could
contribute to the conduction disorders and arrhythmias occasionally reported and participate in the
postural hypotension observed in bortezomib treated patients [27].
5. Muscle Toxicity: The Neglected Adverse Event
Patients with MM can develop several neurological complications caused either by the disease
itself or by the toxic effects of the medications used to treat it. The involvement of skeletal muscle is
considered very rare in MM and has been reported in the concurrent immunoglobulin light chain (AL)
amyloidosis or as the result of long-lasting corticosteroid therapy [153]. Based on initial data from
the phase II SUMMIT and CREST studies in relapsed and/or refractory MM, muscle weakness is a
frequent adverse effect of bortezomib therapy, with the incidence of any grade and grade 3 events in
patients of 11% and 4–5%, respectively [29,154]. Despite these elevated rates of weakness in patients,
a detailed description and evaluation of skeletal muscle involvement with bortezomib was lacking in the
literature. Recently, a small-sized single-center prospective study on 24 newly diagnosed symptomatic
MM patients pointed out that bortezomib treatment may cause a myopathy [155]. Seven out of
14 patients receiving bortezomib complained of difficulty in climbing stairs and rising from a chair and
developed a symmetrical proximal lower limb muscle weakness involving predominantly thigh flexors.
All patients had serum creatine kinase (CK) within the normal reference range. Nerve conduction
studies were normal, and needle electromyography (EMG) recorded myopathic features including
small, polyphasic units, and fast recruitment. Bortezomib-induced myopathy was an early complication
occurring within the four 3-week cycles of therapy and did not progress, remaining confined to the legs.
Muscle weakness was potentially reversible, with 43% of patients experiencing symptom resolution in a
median of 3.6 months with drug interruption. The mechanisms underlying the pathogenesis of muscle
injury in these patients has not been fully clarified. A muscle biopsy from a symptomatic MM patient
treated with bortezomib revealed abnormalities compatible with a metabolic myopathy characterized
on morphological grounds by the accumulation of lipid droplets in several muscle fibers and by
mitochondrial alterations consisting of swelling and cristae loss at ultrastructural examination [155].
These pathological findings were reproduced in an in vitro model, indeed, primary human myoblasts
exposed to bortezomib within the dose range found in the plasma of treated patients presented
excessive storage of lipid droplets together with structural and functional mitochondrial abnormalities,
and without being affected by cytotoxic effects of the drug [155]. In line with one of the main mechanisms
of cardio- and neurotoxicity induced by bortezomib [76,78–81,137,156], in vitro findings were consistent
with the ability of the drug to impair the mitochondria whose dysfunction may lead to an increase
in intracellular lipid content in skeletal muscle [155]. Myogenin, a muscle-specific transcription
factor [157], has also been suggested as a possible intracellular target for bortezomib-induced muscle
toxicity. It has been observed that the treatment of C2C12 mouse myoblast cell line with bortezomib at
clinically relevant doses led to myogenin down-regulation with the consequent inhibition of myotubes
formation and cell cycle arrest at the G2/M phase [158].
Due to the possible clinical relevance of bortezomib-induced muscle toxicity, our group developed
an experimental mouse model to further elucidate the mechanisms responsible for muscle damage.
Adult female mice were treated with bortezomib at a dose of 1 mg/kg twice weekly for 7 or 14 days
and morphological studies including light microscopy and transmission electron microscopy were
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performed on skeletal muscle tissue (see File S1 (Supplementary Materials) for the detail description of
Materials and Methods). One week after the administration of bortezomib, chymotrypsin-like activity
of the proteasome was markedly reduced in blood and skeletal muscle of treated mice compared to the
control group (Figure 3). After 14 days of treatment, the chymotrypsin-like activity partially recovered
but still was significantly lower in blood as well as in the muscle tissue of mice receiving the drug than
in control mice (Figure 3). Histological analysis did not show morphological changes of vastus lateralis,
gastrocnemius, and tibialis anterioris muscles in mice exposed to bortezomib for one or two weeks
(Figure 4). Neither necrotic or regenerating muscle fibers nor increased perimysial or endomysial
connective tissue was observed in hematoxylin and eosin (H&E) and modified Gomori trichrome
(Figure 4). All other histochemical stainings including nicotinamide adenine dinucleotide-tetrazolium
reductase (NADH-TR), cytochrome c oxidase (COX), succinate dehydrogenase (SDH), Periodic acid
Schiff (PAS) and Sudan black were normal. The ultrastructural analysis of muscles obtained from
bortezomib-treated mice, however, revealed morphological abnormalities of mitochondria, which were
enlarged and had a significantly higher cristae density, more commonly in the subsarcolemmal
compartment (Figure 5). Moreover, the lateral sacs of sarcoplasmic reticulum were in various stages of
dilation but retained their triadic structure (Figure 5). All these changes were more evident in mice
after 14 days of treatment. Neither storage of lipid droplets nor morphological evidence of apoptosis
or necrosis was observed in any muscle samples. These findings indicate that bortezomib may exert
a toxic effect on mitochondria in skeletal muscle fibers in healthy C57BL/6 mice, suggesting that
“mitotoxicity” could represent a common mechanism responsible for the toxicity induced by the PI
in the different tissues, including peripheral nerve and heart. Further studies are needed to clarify
whether the changes of mitochondrial morphology observed in muscles of bortezomib-treated mice
result in their functional impairment and to identify the exact intracellular targets of bortezomib in
skeletal muscle.
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intensity ± SD; n = 3; * p < 0.05 vs controls in one-way Anova with Dunnet’s post hoc test.
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morphological abnormalities in control mice and in mice treated with bortezomib. Images were
obtained with obj ×20. Bars: 100 µm.
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Figure 5. Transmission electron micrographs of gastrocnemius muscles from control mice (A,B)
and mice treated for 14 days with bortezomib (C–E). Note the large-sized subsarcolemmal (sm) and
intermyofibrillar (im) mitochondria in C and E compared to the mitochondria in A and B, and the
sarcoplasmic enlargements in D (asterisks). Nucleus (n). Bars: 500 nm. (F) Histograms in F show
the mean ± SE values of secti al rea and inner/outer membrane ratio of subsarcolemmal and
intermyofibrillar mitochondria in gastrocnemius muscles from control mice and mice treated for 7 or
14 days with bortezomib. All values are significantly different from each other.
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6. Conclusions
Bortezomib has shown remarkable clinical benefits in the treatment of MM but is associated
with various adverse events that may lead to early discontinuation of the therapy. Despite peripheral
neuropathy is recognized as the main non-hematologic dose-limiting adverse effect, cardiovascular and
muscular complications are relatively common and potentially reversible. Therefore, their identification
and management are crucial to provide an optimal therapeutic strategy and improve long-term
outcomes. Patients treated with bortezomib should undergo cardiac surveillance and be carefully
monitored by a neurologist for neuromuscular signs and/or symptoms.
In vivo and in vitro studies have documented a significant alteration of the morphology and/or
function of mitochondria in peripheral nerves as well as in cardiac and skeletal muscle, suggesting
that they might be a common target of bortezomib toxicity in these tissues. The mechanisms
underlying the drug-induced mitochondrial defects are partially known, hampering the development
of effective therapeutic strategies able to prevent or reverse them, without interfering with the
anti-tumor activity. Modulators of oxidative phosphorylation, ROS scavengers, compounds that boost
endogenous antioxidant responses, and drugs preventing the mitochondrial p53 accumulation or able
to modulate the mitochondrial metabolism may be suitable for managing the effects of bortezomib on
mitochondria [159]. However, single small-sized studies that evaluated the efficacy of acetyl-L-carnitine,
methylcobalamin, and a nutraceutical compound (docosahexaenoic acid, α-lipoic acid, vitamin C,
and vitamin E) for the prevention of bortezomib-related peripheral neuropathy do not allow to draw
firm conclusions on their therapeutic benefits [78,160,161]. Hopefully, available experimental models
will help us to further clarify the pathophysiology of mitochondrial toxicity induced by bortezomib,
providing valuable information for possible strategies aimed at overcoming these effects.
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